SCHEMBL698984

SCHEMBL698984

CS(=O)(=O)N1CCC(Nc2n[nH]c3c2nc(-c2c(F)cccc2F)c2cc(CO)ccc23)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.43
CDK2 P24941 8/20 0.41
CCND1 P24385 7/20 0.41
CDK1 P06493 5/20 0.41
CDK4 P11802 4/20 0.41
CNR1 P21554 1/20 0.40
TDO2 P48775 1/20 0.37
CCNE1 P24864 5/20 0.36
CCNB1 P14635 2/20 0.36
CCNB2 O95067 1/20 0.36
CCNE2 O96020 1/20 0.36
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36
CDK6 Q00534 4/20 0.36
CCND3 P30281 1/20 0.36
CARM1 Q86X55 1/20 0.35
CCNT1 O60563 1/20 0.35
CDK9 P50750 1/20 0.35
RORC P51449 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700496 0.93 MAPK14 (0.35) MAPK14CDK2CCND1CDK1CDK4
SCHEMBL702396 0.93 MAPK14 (0.43) MAPK14CDK2CCND1CDK1CDK4
SCHEMBL703045 0.89 MAPK14 (0.51) MAPK14CDK2CCND1CDK1CDK4
SCHEMBL702868 0.87 MAPK14 (0.46) MAPK14CDK2CCND1CDK1CDK4
SCHEMBL708407 0.87 MAPK14 (0.43) MAPK14CDK2CCND1CDK1CDK4
SCHEMBL704772 0.86 CDK2 (0.44) MAPK14CDK2CCND1CDK1CDK4
SCHEMBL31448368 0.86 CDK2 (0.44) MAPK14CDK2CCND1CDK1CDK4
SCHEMBL708901 0.86 MAPK14 (0.43) MAPK14CDK2CCND1CDK1CDK4
SCHEMBL704347 0.86 MAPK14 (0.43) MAPK14CDK2CCND1CDK1CDK4
SCHEMBL2680449 0.86 MAPK14 (0.43) MAPK14CDK2CCND1CDK1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421864-B1 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-08-06 EP claimed
EP-2421864-B1 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-08-06 EP disclosed
US-8461175-B2 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2013-06-11 US disclosed
US-20120115898-A1 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-05-10 US disclosed
EP-2421864-A1 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-02-29 EP disclosed
WO-2010122272-A1 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115898-A1 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CBR3, CYP4F3, HCCS MAPK14 4041/4885CDK2 968/4885CCND1 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.